Logo
Neuramis Deep (with Lidocaine)

Neuramis Deep (with Lidocaine)

Neuramis

Aesthetic / Medical Device
  • CE marked (manufacturer/distributor claims for Neuramis series in EU/EEA markets).
  • Manufactured in facilities claiming compliance with regional regulatory standards and quality controls (manufacturer: Medytox).
  • Hyaluronic acid raw material registered in DMF/EDQM or equivalent per manufacturer/distributor statements (verify local regulatory documentation).
Hyaluronic Acid Dermal Filler (Deep volumising / wrinkle correction)

Description

Neuramis Deep with Lidocaine is a stabilized, cross-linked hyaluronic acid (HA) dermal filler formulated for correction of moderate-to-deep facial wrinkles and for volume augmentation of cheeks, chin and lips. The product contains HA at 20 mg/mL and includes lidocaine (0.3%) in the gel to improve injection comfort. It is supplied as single-use prefilled 1 mL syringes and is intended for intradermal/subcutaneous injection by trained medical professionals.

Bnefits

  • High HA concentration (20 mg/mL) for deeper volume replacement and correction of folds.
  • Includes lidocaine (0.3%) for reduced injection pain and improved patient comfort.
  • SHAPE™ two-step cross-linking and purification process (manufacturer claim) for gel stability and long-lasting effect.
  • Designed for natural-looking correction of nasolabial folds, marionette lines, cheek/chin augmentation and lip contouring.
  • Low residual BDDE levels per manufacturer quality specifications.

Indications

  • Correction of moderate-to-severe facial wrinkles and folds (e.g., nasolabial folds).
  • Volume augmentation (cheeks, chin, jawline) and lip enhancement where a deeper filler is indicated.
  • Use by qualified medical practitioners for aesthetic facial procedures.

Composition

  • Hyaluronic acid (cross-linked) — 20 mg/mL (2.0% w/v)
  • Lidocaine (as hydrochloride) — 0.3% w/w (which corresponds to approximately 3 mg/mL)
  • Crosslinking agent residuals present at levels compliant with manufacturer quality controls (BDDE residuals reported as very low by manufacturer)
  • Excipients and sterile water for injection (complete INCI/IFU available in manufacturer documentation)

Formulation

  • Sterile, transparent, viscoelastic gel in prefilled 1 mL syringe for intradermal/subcutaneous injection. Single-use medical device (Class III in EU classifications for dermal fillers).

Packaging

  • Prefilled 1 mL syringe (single dose). Boxed units containing 1 x 1 mL (and larger multi-pack configurations offered by some distributors).

Usage

  • Intended for administration by trained medical professionals experienced in dermal filler injections.
  • Follow aseptic technique and local injection protocols (depth, volume and technique per treatment area).
  • Use standard pre- and post-injection precautions (patient history, allergy check, informed consent).
  • Have hyaluronidase available for potential adverse events requiring filler dissolution.

Contraindications

  • Active infection or inflammation at the injection site.
  • Known hypersensitivity to any component of the product (including lidocaine or HA).
  • Patients with severe allergies, history of anaphylaxis, or sensitivity to gram-positive bacterial proteins used in HA production (if applicable).
  • Not indicated for use in areas with thin skin where deep fillers are inappropriate, unless clinician deems suitable.

Adverse Effects

  • Common, usually transient: swelling, redness, pain/tenderness, bruising, itching at injection site.
  • Less common but serious: infection, vascular occlusion, granuloma formation, nodules, hypersensitivity/allergic reactions.
  • Lidocaine-related adverse effects possible in rare systemic exposure (dizziness, allergic reaction) — typically minimal with correct administration.

Storage Conditions

  • Store in original packaging at controlled room temperature as specified in the product IFU (avoid freezing and excessive heat).
  • Protect from direct sunlight and keep out of reach of children.

Duration

Clinical durability reported commonly around 9\u201312 months depending on treatment area and patient factors; individual results vary.

Onset

Immediate volumising/correction effect after injection; final integration and settling over days to weeks.

Browse more Aesthetic / Medical Device

Top Treatments

Top Cities in the UK